Jonathan Violin - 01 Feb 2022 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: VRDN
Reported as of: 01 Feb 2022
Net transaction value: -$572,818
SEC form: 4
Accepted by SEC: 03 Feb 2022, 17:11:27 UTC
Prior SEC filing: 10 Dec 2021
Next SEC filing: 03 Mar 2022
Source filing: View source filing
Reporting owner signature: /s/ Lara Meisner, Attorney-in-Fact for Jonathan Violin

Key filing fact

Jonathan Violin filed Form 4 for Viridian Therapeutics, Inc.\DE (VRDN) on 03 Feb 2022.

Key facts

This page summarizes Jonathan Violin's Form 4 filing for Viridian Therapeutics, Inc.\DE (VRDN).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Feb 2022, 17:11.

Change

Previous filing in this sequence was filed on 10 Dec 2021.
Current net transaction value: -$572,818.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VRDN transaction

Common Stock

Sale

Transaction value: $327,482
Shares: -16,751
Change %: -2.7%
Price: $19.55
Shares after: 614,154
Date: 01 Feb 2022
Ownership: Direct
Footnotes: F1

VRDN transaction

Common Stock

Sale

Transaction value: $227,920
Shares: -12,340
Change %: -2%
Price: $18.47
Shares after: 601,814
Date: 02 Feb 2022
Ownership: Direct
Footnotes: F2

VRDN transaction

Common Stock

Sale

Transaction value: $17,416
Shares: -909
Change %: -0.15%
Price: $19.16
Shares after: 600,905
Date: 03 Feb 2022
Ownership: Direct
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VRDN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +280,000
Change %
Price: $0.000000
Shares after: 280,000
Date: 02 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 280,000
Exercise price: $18.51
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.90 to $20.23. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Footnote F2

This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.32 to $19.49. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Footnote F3

This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.04 to $19.66. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Footnote F4

The option vests in equal monthly installments through February 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.